Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
2023-10-22 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We have been surprised...
2023-10-20 11:12:54 ET More on Merck Merck: Right On Time Merck Vs. GSK: The Game-Changer Race In Pharma Excellence Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects Merck study shows Keytruda can help lower death risk from cervical canc...
2023-10-19 23:52:31 ET More on Daiichi, Merck, etc. Merck: Right On Time Merck Vs. GSK: The Game-Changer Race In Pharma Excellence Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects AstraZeneca drops after Phase 3 data for lung cancer the...
2023-10-18 10:25:26 ET More on AstraZeneca, Daiichi, etc. AstraZeneca: Hidden Gem Of The Pharma Sector Is A Great Buy Opportunity AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths Daiichi Sankyo Company, Limited (DSKYF) Q1 2023 Earnings Call Transcript ...
2023-10-13 11:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
2023-09-22 07:25:38 ET More on AstraZeneca Seeking Alpha’s Quant Rating on AstraZeneca Historical earnings data for AstraZeneca AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths AstraZeneca: Robust Performance And Promising Growth Initiati...
2023-09-15 11:05:45 ET More on Lilly, Ascendis, and Novartis Eli Lilly: A Potential Game Changer For Weight Management And Cardiovascular Health Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge Sandoz to commercialize biosimilar to J&J blockbuster drug ...
2023-09-03 03:45:00 ET Summary Shanghai GenFleet Technologies partners with Verastem in a deal worth up to $625.5 million for three preclinical small-molecule candidates for RAS pathway-driven cancers. Shanghai Kangpu Biopharmaceuticals raises $13.8 million in a B funding round to...
2023-08-31 09:58:25 ET More on AstraZeneca AstraZeneca: Robust Performance And Promising Growth Initiatives AstraZeneca's Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade) AstraZeneca: Solid Earnings Report Reinforces Medium To Long-Term Upside ...
2023-08-29 08:46:13 ET Summary Esperion reported Q2 bempedoic acid revenue of $20.3M; we expect the bempedoic acid to surpass the 2023 consensus numbers. The ongoing Daiichi litigation poses a significant weight on Esperion's stock price and financials, but at this valuation, risk...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...